Allergan's most recent trend suggests a bullish bias. One trading opportunity on Allergan is a Bull Put Spread using a strike $267.50 short put and a strike $262.50 long put offers a potential 31.58% return on risk over the next 24 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $267.50 by expiration. The full premium credit of $1.20 would be kept by the premium seller. The risk of $3.80 would be incurred if the stock dropped below the $262.50 long put strike price.
The 5-day moving average is moving down which suggests that the short-term momentum for Allergan is bearish and the probability of a decline in share price is higher if the stock starts trending.
The 20-day moving average is moving up which suggests that the medium-term momentum for Allergan is bullish.
The RSI indicator is at 49.23 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Allergan
3:43 am Allergan acquires rights to Ironwood's (IRWD) CONSTELLA; AGN also receives rights to LINZESS in Mexico
Tue, 27 Oct 2015 07:43:00 GMT
Allergan Acquires Rights To Ironwood's CONSTELLA® (Linaclotide) From Almirall In More Than 40 Countries
Tue, 27 Oct 2015 07:30:00 GMT
PR Newswire – DUBLIN and CAMBRIDGE, Mass., Oct. 27, 2015 /PRNewswire/ — Allergan plc (AGN), a leading global pharmaceutical company, and Ironwood Pharmaceuticals, Inc. (IRWD) today announced that Allergan has acquired rights to CONSTELLA® (linaclotide) in the European Union, Switzerland, Turkey and the Commonwealth of Independent States from Almirall, S.A. and has also reacquired rights to LINZESS® (linaclotide) in Mexico from Almirall.
TIMELINE-Deals, and doubts, mark Valeant's acquisition history
Mon, 26 Oct 2015 23:03:25 GMT
Controversial pharma CEO Martin Shkreli bails on Valeant bet
Mon, 26 Oct 2015 22:38:33 GMT
Reuters – The one-time hedge fund executive now running a biotech firm at the center of a drug-pricing controversy on Monday said he has bailed from a losing bet he made on another contentious drug maker: Valeant Pharmaceuticals International Inc (VRX.TO) (VRX.N). On the day last week that Valeant shares plunged in response to a shortseller's accusation of accounting irregularities, Martin Shkreli, head of Turing Pharmaceuticals, took to Twitter to say he had bought shares of Valeant while at the same time selling short the shares of rival Allergan Plc (AGN.N), a transaction known as a pairs trade. Onward and upward,” Shkreli tweeted, just hours after Valeant laid out a detailed defense against the accusations of accounting fraud.
Controversial pharma CEO Martin Shkreli bails on Valeant bet
Mon, 26 Oct 2015 22:33:35 GMT
Related Posts
Also on Market Tamer…
Follow Us on Facebook